Saltar al contenido
Merck

Conformational remodeling of the fibronectin matrix selectively regulates VEGF signaling.

Journal of cell science (2014-07-02)
Anthony Ambesi, Paula J McKeown-Longo
RESUMEN

The fibronectin matrix plays a crucial role in the regulation of angiogenesis during development, tissue repair and pathogenesis. Previous work has identified a fibronectin-derived homophilic binding peptide, anastellin, as an effective inhibitor of angiogenesis; however, its mechanism of action is not well understood. In the present study, we demonstrate that anastellin selectively inhibits microvessel cell signaling in response to the VEGF165 isoform, but not VEGF121, by preventing the assembly of the complex containing the VEGF receptor and neuropilin-1. Anastellin treatment resulted in the inactivation of α5β1 integrins but was not accompanied by a change in either adhesion complexes or adhesion-based signaling. Integrin inactivation was associated with a masking of the fibronectin synergy site within the extracellular matrix (ECM), indicating that α5β1 inactivation resulted from a decrease in available ligand. These data demonstrate that anastellin influences the microvessel cell response to growth factors by controlling the repertoire of ligated integrins and point to anastellin as an effective regulator of fibronectin matrix organization. These studies further suggest that homophilic fibronectin binding peptides might have novel applications in the field of tissue regeneration as tools to regulate neovascularization.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Anticuerpo anti-fosfotirosina, clon 4G10 ®, clone 4G10®, Upstate®, from mouse
Sigma-Aldrich
Anti-Integrin β1 Antibody, clone 12G10, clone 12G10, Chemicon®, from mouse
Sigma-Aldrich
O-Phospho-L-tyrosine
Sigma-Aldrich
Anticuerpo anti-integrina αVβ5, clon 15F11, sin azida, clone 15F11, Chemicon®, from mouse
Sigma-Aldrich
Anti-phospho-VEGFR2/Flk-1/KDR (Tyr1054) Antibody, Upstate®, from rabbit
Sigma-Aldrich
MISSION® esiRNA, targeting human NELL1 (1)
Sigma-Aldrich
MISSION® esiRNA, targeting human NRP1